Objective: The type 1 fibroblast growth factor receptor (FGFR-1) is the only high affinity receptor for fibroblast growth factor-2 (FGF-2) in the rat myocardium, and is essential for normal growth and development of the heart. Levels of FGFR-1 are developmentally regulated, being high in embryonic cardiac myocytes. Also, FGFR-1 exists as both 'long' and 'short' isoforms, and there is a switch from predominant expression of the 'long' isoform in the embryo to the 'short' isoform in the adult heart. Both the decrease in receptor levels and the isoform switch in postnatal cardiac myocytes correlate with a loss of proliferative potential. We investigated whether an increase in either 'long' or 'short' FGFR-1 isoforms could stimulate proliferation in postnatal rat cardiac myocyte cultures. Methods and Results: Previously we cloned cDNAs corresponding to 'long' (L) and 'short' (S) FGFR-1 isoforms from embryonic mouse hearts. Hybrid FGFR-1(L) and (S) genes, directed by a myosin light chain-2 promoter and SV40 enhancer sequences, were generated and used to transiently transfect neonatal rat cardiac myocytes. Overexpression of FGFR-1 mRNA and protein was detected by RNA blotting and immunocytochemistry. Ligand-crosslinking confirmed the presence of specific receptors capable of binding FGF-2 on the cell membrane. Overexpression of either FGFR-1(L) or (S) was associated with stimulation of proliferation as assessed by significant increases in bromodeoxyuridine uptake (DNA synthesis) and cell number. To determine whether this response was FGF-2 specific, the level of FGF-2 was assessed in the culture medium of cardiac myocytes overexpressing FGFR-1 isoforms. A three-fold increase was detected in the media of cardiac myocytes overexpressing either FGFR-1(L) or (S) compared to control levels. Neutralization of this FGF-2 with antibodies inhibited the proliferative response. Conclusion: Overexpression of either FGFR-1(L) or (S) resulted in an increase in FGF-2-mediated proliferation of postnatal rat cardiac myocytes.
Introduction
the rat heart [5, 8, 10] . FGFR-1 consists of three domains: a ligand binding domain containing immunoglobulin-like Fibroblast growth factor-2 (FGF-2) is a multifunctional (Ig-like) loops I-III, a membrane-spanning domain, and a protein that plays a vital role in regulating growth and functional tyrosine kinase domain. There are two prevalent differentiation of various cell types including cardiac FGFR-1 isoforms, 'long' and 'short', which occur through myocytes. FGF-2 exerts many of its effects by binding to alternative splicing of RNA corresponding to a region of specific high affinity cell surface receptors (FGFR) of the the ligand binding domain [9, 11] . The 'long' and 'short' tyrosine kinase family [1, 2] . The FGFR family includes isoforms contain three (I-III) and two (II and III) Ig-like four members (FGFR-1, 2, 3 and 4) [3] [4] [5] [6] [7] [8] [9] [10] , however, loops, respectively. It has been suggested that binding to FGFR-1 is the only high affinity receptor detected so far in low affinity binding sites on the cell surface, consisting of heparin sulfate proteoglycans (HSPG), plays a vital func-tion in the binding of FGF-2 to its high affinity receptor Experimental Animals published by the Canadian Council [12, 13] . However, some evidence indicates that FGF can on Animal Care. signal via the HSPGs independently of the FGFR [14] .
FGFR-1 plays an essential role in the development of 2.2. Cell transfections the heart [15, 16] . Studies show that a mutant form of FGFR-1 in Drosophila (heartless) was unable to induce For gene transfer, cardiac myocytes were plated at 6 6 formation of cardiac muscle from mesoderm [17] . Also, 1.3310 cells per 60-mm dish or 0.7-0.9310 cells per knockout of FGFR-1 function during early avian develop-35-mm dish and were maintained in serum containing ment results in inhibition of cardiac muscle growth and F12-DMEM nutrient mixture. Transient transfection of improper looping of the heart [18] . In the developing heart, cardiac myocytes was done using the calcium phosphate / embryonic cardiac myocytes are highly proliferative, how-DNA precipitation method [22] . Briefly, cells were transever, postnatal maturation results in a loss of their proliferfected 24 h after plating with 10 mg of test plasmid DNA. ative potential and they enter a state of, presumably, After 24 h, cells were refed with growth medium and terminal differentiation in the adult heart [19] . RNA maintained for a further 48 to 72 h before processing. analysis of embryonic versus postnatal hearts reveals a
Hybrid genes for transfection included: full-length cDNAs significant decrease in FGFR-1 levels, as well as a switch for both long and short mouse FGFR-1 fused to a cardiac in the relative levels of the 'long' versus 'short' isoform specific myosin light chain-2 (MLC-2) promoter with [9, 10, 20] . The 'long' and 'short' FGFR-1 mRNAs presimian virus 40 (SV40) enhancer sequences to generate dominate in the embryonic and adult heart, respectively.
SVenhMLCp.FGFR(L) and SVenhMLCp.FGFR(S), reBoth the decrease in FGFR-1 levels and the isoform spectively, as previously described [23] . The expression switching correlate with the transition of cardiac myocytes vector containing the promoter, but with the fire fly from a hyperplastic to a hypertrophic and non-proliferative luciferase gene instead of any FGFR-1 sequences was used phenotype. Thus, we investigated the possibility that an as a control (SVenhMLCp.luc). Generation and characteriincrease in FGFR-1 levels, and or changing the relative zation of these hybrid genes were described previously levels of the 'long' versus 'short' isoform, might increase [23, 24] . the proliferative potential of postnatal cardiac myocytes.
Transfection efficiency was assessed using the b-galPreviously, we cloned FGFR-1 cDNAs from embryonic actosidase assay [25] . Cardiac myocytes, co-transfected mouse heart corresponding to both 'long' and 'short ' with RSVp.bgal as described above, were rinsed with isoforms [9] . Here we report the effect of FGFR-1 isoform calcium and magnesium-free PBS, fixed (1.8% formaldeexpression, directed by a myosin light chain-2 promoter hyde, 0.2% glutaraldehyde, 0.002 mol / l magnesium chloand SV40 enhancer sequences, on DNA synthesis and cell ride, 50 mM sodium phosphate, pH 7.4) and incubated in number in transiently transfected neonatal rat ventricular an X-gal solution containing 1 mM magnesium chloride, cardiac myocytes. We show that both 'long' and 'short' 0.0033 mol / l potassium ferrocyanide, 0.0033 mol / l potas-FGFR-1 cDNAs are expressed in cardiac myocytes, resium ferricyanide, 0.15 mol / l sodium chloride, 0.01 mol / l sulting in increased specific binding of FGF-2 on the cell sodium phosphate buffer pH 7.4 and 0.2% (w / v) X-gal for surface, and stimulation of proliferation in a ligand-depen-18 h at 378C. For quantitative analysis, about 12 000 dent manner. cardiac myocytes were assessed by counting from 15 randomly selected fields on three separate coverslips, representing four independent transfection experiments. The percentage of X-gal stained cells was determined.
Methods
2.3. RNA blotting 2.1. Cell culture Total RNA was isolated from transfected cultures which Postnatal ventricular cardiac myocytes were isolated had been maintained for 48 h in 10% FBS F12-DMEM, from 1-2 day old Sprague Dawley rats by enzymatic using the Trizol-extraction method (Gibco-BRL, Burlindigestion with 0.1% (wt / vol) trypsin (Sigma, St. Louis, gton, ON). Total RNA was denatured with formaldehyde MO) using a temperature regulated (358C) spinner flask, and resolved by electrophoresis through a 1.0% agarose gel followed by fractionation on a Percoll gradient [21] . Cells [26] . The RNA was blotted to nitrocellulose, probed with were counted using a hemocytometer and plated on either radiolabelled mouse FGFR-1 (Xba I / Sal I) or rat collagen-coated dishes in Ham's F10 medium containing FGF-2 (Sma I / Xho I) cDNA fragments and assessed by 10% (v / v) fetal bovine serum (FBS), 10% (v / v) horse autoradiography as previously described [9] . The FGFR-1 serum, 140 mg / ml (w / v) calcium chloride and antibiotics.
cDNA fragment represents a region common to both long Plates were coated using 0.1% (w / v) type 1 collagen stock and short FGFR-1 transcripts [20] , and the rat FGF-2 solution (UBI, Lake Placid, NY). The investigation confragment corresponds to the full length FGF-2 cDNA forms with the current Guide To The Care and Use of deleted of those sequences peculiar to the high molecular weight isoforms [27] . Hybridization with the GAPDH scraped off, followed by centrifugation (10 min, 10 0003 cDNA (Pst I / Bgl I) was used to assess loading and g) and resuspension of the pellet in 30 ml of homogenizing standardise FGFR-1 and FGF-2 mRNA levels. Relative buffer consisting of 0.02 mol / l HEPES pH 7.4, 0.25 mol / l messenger RNA levels were assessed from autoradiogsucrose, 0.001 mol / l ethylenediaminetetraacetic acid, 1 raphs by scanning densitometry. mg / ml aprotinin, 1 mg / ml leupeptin and 1% Triton X-100. neapolis, MN), as directed by the manufacturer's instruc-FGFR-1 isoforms. These antibodies are highly specific and tions. Cardiac myocytes transfected with the control gene do not crossreact with FGFR-2, FGFR-3 and FGFR-4 [28] .
were used to determine basal levels of FGF-2 48 h after Labelling for myosin, to identify myocytes, was performed transfection. using monoclonal antibodies specific for striated muscle myosin (1:50, MF20) in 1% BSA in PBS followed by 2.7. Bromodeoxyuridine (BrdU) labelling visualization with Texas Red conjugated anti-mouse Ig To assess for the specific effect of FGF-2 via cell nuclei was necessary, cellular DNA was stained with surface receptors, cardiac myocyte cultures were exposed 0.0125% Hoechst dye 33342 (Calbiochem-Behring, San to neutralizing antibodies to FGF-2 using conditions Diego, CA). Coverslips were mounted using mounting previously described [22] . Briefly, myocytes were mainmedia for fluorescence (Vector Vectashield; Burlingame, tained for 24 h in either the presence of (i) normal mouse CA), examined and photographed with a Nikon Diaphot Ig (10 mg / ml; Sigma, St.Louis, MO); or (ii) anti-bovine microscope equipped with epifluorescence optics.
FGF-2, type I, monoclonal neutralizing antibodies (10 mg / ml; Upstate Biotechnology), followed by incubation in 2.5. FGFR-1 crosslinking the presence of 3 mg / ml (w / v) BrdU. Myocyte cultures were subsequently fixed with 1% paraformaldehyde for 15 For FGFR-1 crosslinking studies, rat ventricular cardiac min at 48C and then with 70% ethanol for 30 min at room myocytes were plated on collagen-coated dishes, transfecttemperature, followed by treatment with 70 mmol / l soed for 24 h with either SVenhMLCp.FGFR(L) or dium hydroxide for 2 min at room temperature. SVenhMLCp.FGFR(S) as well as control DNA, mainSimultaneous labelling for myosin (to identify tained for 48 h, and incubated with 125I-FGF-2 (2.5 myocytes) and / or BrdU in ventricular myocytes was done ng / sample; Dupont Canada Inc., Mississauga, ON) for 90 using monoclonal antibodies against striated myosin (1:50, min at 48C in the absence or presence of 0.1 mg unlabelled MF20) and BrdU (1:2, Amersham; or 1:7, Becton Dickin-FGF-2 (Upstate Biotechnology, Lake Placid, NY as SVenhMLCp.luc, as a negative control. Samples were representing three or four independent transfection experitransferred to nitrocellulose and probed for FGFR-1 using ments. For DNA synthesis, a BrdU labelling index (LI) a fragment of the cDNA capable of detecting both FGFRwas obtained by expressing the number of cardiac myocyte 1(L) and FGFR-1(S) transcripts (Fig. 1A) . Subsequently, nuclei staining positively for BrdU as a percentage of the the blot was reprobed with GAPDH to allow a stantotal number (|2000 per construct) of cardiac myocyte dardization of RNA levels after densitometry of aunuclei assessed.
toradiographs (Fig. 1B) . A transcript of about 4.3 kb, reflecting endogenous FGFR-1 mRNA and consistent with 2.8. Cell number the expected size for FGFR-1(L) [9, 20] , was detected in the control lane using the FGFR-1 probe (lane a). TransCardiac myocytes were plated and transfected as defection with the FGFR-1(L) cDNA resulted in about a scribed for the 'Bromodeoxyuridine Labelling' experiten-fold increase in the intensity of the 4.3-kb transcript ments above. After 48 h, myocytes were rinsed with PBS, (lane b). In contrast to the low level of endogenous and fixed with 1% paraformaldehyde for 15 min at 48C.
FGFR-1(L) RNA observed, no endogenous FGFR-1(S) Cardiac myocytes were labelled for myosin using mono-RNA was detected. As a result, transfection with the clonal antibodies against striated myosin (1:50, MF20) and FGFR-1(S) cDNA resulted in the induction of a 4.1 kb visualized with Texas red-conjugated anti-mouse Ig (1: 20; transcript consistent with the predicted size of FGFR-1(S) Amersham). Cell number was assessed by counting the RNA (lane c). This estimate was based on the size number of myocytes from 15 randomly selected fields on at least three coverslips representing two independent experiments. Cell number was expressed as the fold difference relative to control, which was arbitrarily set to 1.0.
Statistical analysis
Data presented in the text and figures are represented as mean plus or minus standard error from the mean from at least two independent experiments each done in triplicate, unless stated otherwise. Statistical analysis of the results was done using the non-parametric Mann-Whitney test and ANOVA with Dunn's multiple-comparison post hoc test. Results were considered significant if P was determined to be ,0.05.
Results

FGFR-1 mRNA levels are increased in neonatal cardiac myocytes transiently transfected with FGFR-1(L) and (S) cDNAs.
Neonatal (1-2 days) rat ventricular myocyte cultures were used to test the expression of the FGFR-1 cDNA [9, 20] . Minor forming on the membrane. A further band of 135 kDa was bands were also detected at 4.3 and 4.0 kb, which likely only present in the sample resulting from FGFR-1(S) reflect endogenous FGFR-1(L) RNA and an alternative cDNA expression, and gave rise to a four-fold (n52, 6 FGFR-1(S) transcript, respectively. A further minor trandeterminations) increase in overall receptor (1351155 script of 1.6 kb was also detected that was common to kDa) levels (lane c). Overexpression of the FGFR-1(L) cardiac myocytes transfected with either FGFR-1(L) or (S) cDNA resulted in a seven-fold (n52, 6 determinations) cDNAs (lanes b and c) . This transcript initiates, presumabincrease in the intensity of the 155-kDa sized band ly, from an internal start site downstream of the first Ig compared to control. Both the 155-kDa band in the control loop-like domain, since this loop sequence would be and FGFR-1(L) related samples as well as the 135-kDa absent from the FGFR-1(S) cDNA [9] . It is possible that band in the FGFR-1(S) related samples were competed this transcript is also generated from the endogenous effectively in the presence of nonradiolabelled FGF-2 FGFR-1 gene, but is not detected because of the relatively (lanes b,f,j). The 155 and 135-kDa values for the FGF-2 / lower levels of expression.
FGFR-1(L) and FGF-2 / FGFR-1(S) complexes would be consistent with receptor sizes of about 137 and 117 kDa,
Subcellular localization of FGFR-1 isoforms in
respectively, after subtracting 18 kDa for FGF-2. The neonatal cardiac myocytes bands with mobilities corresponding to proteins of about 35 and 50 kDa likely reflect crosslinked multimers of Immunofluorescence microscopy was used to visualize radiolabelled FGF-2 as described previously [10] . FGFR-1 protein in neonatal rat cardiac myocytes transfected with control plasmid (SVenhMLCp.luc) as well as 3.4. DNA synthesis and cell number are increased FGFR-1(L) and (S) cDNAs (Fig. 2) . Cells were doublesignificantly in neonatal cardiac myocyte cultures labelled for myosin and FGFR-1 to specifically identify transfected with FGFR-1 cDNAs myocytes expressing FGFR-1. The endogenous pattern of FGFR-1 localization was assessed in cultures transfected
The effect of FGFR-1 isoform overexpression on DNA with control plasmid. The overall FGFR-1 specific staining synthesis and cell number were assessed as markers of was relatively weak. FGFR-1 was localized to the perinucardiac myocyte proliferation in cultures maintained in the clear region and a speckled pattern of staining was present presence of 10% FBS-DMEM. Immunofluorescence stainin some nuclei. In cultures transfected with FGFR-1 (L) or ing with monoclonal antibodies to myosin and BrdU were (S) cDNAs (but not control), intense and specific staining used to determine a BrdU labelling index (LI), or the for FGFR-1 was observed. This was considered to repreproportion of myocytes undergoing DNA synthesis (Ssent localization of FGFR-1 in overexpressing cardiac phase nuclei) in cultures transfected with FGFR-1 cDNAs myocytes. The majority of these overexpressing cells or a control gene. Anti-BrdU staining was confined to the displayed strong perinuclear staining and or 'particles' nucleus, whereas anti-myosin staining was exclusively staining intensely for FGFR-1 extended out along the cytoplasmic in the rat cardiac myocytes. The results are length of the myocyte (Fig. 2) .
shown in Fig. 4A and are presented as the proportion of myocytes staining for BrdU and, thus, showing evidence of 3.3. Overexpression of FGFR-1 isoforms increases DNA synthesis. There was a significant |three-fold inspecific binding of 125I-FGF-2 on neonatal cardiac crease in the number of myocyte nuclei staining for BrdU myocyte membranes in cultures transfected with SVenMLCp.FGFR-1(S) (2.6 fold) and SVenMLCp.FGFR-1(L) (2.8 fold) compared Crosslinking and SDS-PAGE were used to determine with cells transfected with control plasmid (P,0.001, whether transfection of neonatal rat cardiac myocytes with n54). There was no significant difference between the FGFR-1 cDNAs increased specific FGF-2 binding on the results obtained following overexpression of the 'short' cell membrane, and, thus, the presence of receptors capable versus 'long' FGFR-1 isoforms. of binding FGF-2. Cardiac myocytes were transfected with Myosin positive cells were also scored in 15 random expression plasmids containing FGFR-1 cDNAs or control fields per coverslip (n53) to determine whether the DNA. Following transfection, cardiac myocytes were increase in BrdU staining (Fig. 4A ) also reflected an maintained for 48 h and incubated for 90 min with increase in cardiac myocyte cell number (Fig. 4B) . iodinated FGF-2 in the absence or presence of greater than Myocyte number was significantly increased (|1.7 fold) in 40-fold molar excess of non-radiolabelled FGF-2. Memcultures transfected with SVenMLCp.FGFR-1(S) or branes were isolated after crosslinking with DSS and SVenMLCp.FGFR-1(L) compared with cells transfected analyzed by SDS-PAGE and autoradiography (Fig. 3) . In with control SVenMLCp.luc plasmid (P,0.001, n53) the absence of 'cold' FGF-2, samples from cardiac (Fig. 5B) . Myocyte number was not significantly different myocytes transfected with control DNA (lane a) or FGFRin cultures overexpressing FGFR-1(S) versus FGFR-1(L) 1(S) (lanes c-e) and FGFR-1(L) cDNAs (lanes g-i) (Fig. 4B) . assay) was used to detect FGF-2 in samples of conditioned media from myocyte cultures transfected with FGFR-1(S), FGFR-1(L) cDNAs or control DNA after 48 h. A standard toradiographs. A 6.0-kb FGF-2 transcript was detected in curve for FGF-2 levels in the conditioned media was all samples. After correction for RNA loading, the levels established using human FGF-2 (0-32 pg / ml). The levels of FGF-2 mRNA were not different between cultures of FGF-2 in the conditioned medium of cultures transfecttransfected with control, FGFR-1(L) or (S) DNA. ed with SVenhMLCp.luc, SVenhMLCp.FGFR-1(S) or SVenhMLCp.FGFR-1(L) were determined and the results 3.6. The increase in DNA synthesis with FGFR-1 are expressed as mean values (pg / ml) from at least nine overexpression is blocked with neutralising antibodies to determinations (Fig. 5A) . A level of 0.12 pg / ml was FGF-2 observed in cultures transfected with control (SVenhMLCp.luc) plasmid DNA. However, the levels of FGF-2 in the We reexamined the BrdU LI in the presence of neutralisconditioned medium of cultures overexpressing FGFRing antibodies to FGF-2 to determine whether the in-1(S) or FGFR-1(L) were 3.2 and 2.9 fold higher, respeccreased proliferation seen in FGFR-1 overexpressing cultively (P,0.05, n59) (Fig. 5A) . Subsequently, RNA was tures was FGF-2 dependent (Fig. 6 ). Cultures were incuisolated from these cultures, and assessed for FGF-2 bated with normal mouse serum (NMS) as a control for the expression by RNA blotting (Fig. 5B) . The blot was also mouse anti-FGF-2 serum. A significant two to three fold probed for GAPDH to allow standardisation of FGF-2 increase in BrdU LI was seen with both FGFR-1(S) and mRNA levels following densitometry of resulting au-(L) transfected versus control cells in the presence of striated muscle myosin (Fig. 2) . The FGFR-1 antibodies were raised to the intracellular kinase domain and, thus, mouse Ig (P,0.001, n53). The presence of neutralizing recognize an epitope common to both FGFR-1(L) and antibodies against FGF-2 (10 mg / ml) blocked this increase FGFR-1(S). Finally, as evidence of an increase in FGFR-1 so that there was no significant difference between the levels, the presence of increased levels of specific plasma BrdU LI for cardiac myocytes transfected with FGFR-1 membrane FGF-2 binding sites was detected in cultures cDNAs versus control DNA (P.0.05, n53). Regardless of overexpressing either FGFR-1 isoforms (Fig. 3) . the presence or absence of antibodies, no significant A significant, 2.6-2.8 fold increase in DNA synthesis difference was detected between the effects observed and 1.6-1.8 fold increase in overall cell number ( (Fig. 6) .
proliferation in cultures overexpressing FGFR-1(L) and (S). These increases are quite high and disproportionate to the fraction of myocytes (|10%, based on b-galacto-4. Discussion sidase), expected to be stimulated to divide due to FGFR-1 overexpression, and suggest that all myocytes (not only the With a view to increasing proliferative potential of overexpressing fraction) may have been subjected to postnatal cardiac myocytes, we generated expression vecincreased mitogenic stimulation. Indeed, overexpression of tors containing the myosin light chain-2 promoter and either FGFR-1 (L) or (S) resulted in a three-fold increase in FGF-2 present in the culture medium (Fig. 5A) , thus It has been suggested that expression of 'long' FGFR-1 raising the possibility that increased levels of FGF-2 isoforms correlates with restriction of cell growth, maligcontribute to the overall cardiac myocyte proliferation nancy and enhanced differentiated function [34] . However, observed. Exogenous addition of FGF-2 to the culture this is not supported by the pattern of FGFR-1 mRNA medium has been previously shown to increase neonatal expression in the developing heart. Previously, we used cardiac myocyte proliferation, to a degree similar to the reverse transcriptase-polymerase chain reaction to assess stimulation observed in our study [29] . Furthermore, the the relative levels of FGFR-1(S) versus FGFR-1(L) in stimulatory effect of FGFR-1 overexpression was fully embryonic (dividing) and adult (non dividing) mouse blocked by neutralising antibodies to FGF-2 (Fig. 6) , cardiac myocytes [9] . There appeared to be a switch in the indicating that the increase in overall myocyte proliferation pattern of FGFR-1 expression during development as the is FGF-2 dependent and similar for the 'long' and 'short' 'long' and 'short' RNAs represented the major transcript FGFR-1 isoforms. The mechanism resulting in increased detected in embryonic and adult cells, respectively. Thus, FGF-2 levels in the medium of FGFR-1 overexpressing there was a correlation between predominantly FGFR-1(L) myocytes is not as yet known but it does not appear to expression and a proliferative cardiac myocyte phenotype. include stimulation of FGF-2 mRNA expression (Fig. 5B) .
The presence of endogenous FGFR-1(L) transcript in Signalling by FGF-2 and FGFR-1 has two major neonatal rat cardiac myocytes (Fig. 1) would be consistent components. The first mode is dependent on ligand-plaswith this idea, reflecting a limited proliferative capacity at ma membrane receptor interaction in the extracellular this stage. Although, transfection with the FGFR-1(L) space. The receptor then dimerises, autophosphorylates, cDNA increased cardiac myocyte growth, no significant and can activate downstream signalling cascades, including difference was detected between the levels of stimulation the activation of MAPK which has been associated with of proliferation seen with FGFR-1(L) versus FGFR-1(S) stimulation of proliferation by FGF-2 [30] . The inhibition overexpression (Fig. 4) . Thus, while we have shown that of the stimulatory effect of 'long' or 'short' receptor an increase in either 'long' or 'short' FGFR-1 levels can overexpression on cardiac myocyte proliferation by neustimulate postnatal cardiac myocyte proliferation in an tralising antibodies to FGF-2 (Fig. 6 ), indicate that a FGF-2-dependent manner, there is no evidence that either ligand-dependent triggering mechanism is operating in our of the two receptor isoforms stimulated these effects system. Consistent with this observation, no differences preferentially. The significance, therefore, of the switch to have been reported between the intracellular signaling the 'short' isoform during cardiac development remains to elicited by FGF-2 binding to the 'long' versus 'short' be established. FGFR-1 isoform. The affinity of FGF-2 for the 'long' (50-150 pM) or 'short' (100 pM) FGFR-1 is comparable [11] . Although more controversial, this also appears to be
